HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) was the target of a large growth in short interest in June. As of June 30th, there was short interest totaling 123,640 shares, a growth of 115.9% from the June 15th total of 57,278 shares. Based on an average daily volume of 13,681,823 shares, the short-interest ratio is currently 0.0 days. Currently, 4.1% of the company’s stock are sold short.

Analysts Set New Price Targets

Several research analysts have recently weighed in on HSCS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. Ascendiant Capital Markets cut their price objective on shares of HeartSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

HeartSciences Stock Down 3.8%

Shares of HeartSciences stock traded down $0.10 on Wednesday, reaching $2.52. 16,778 shares of the company were exchanged, compared to its average volume of 1,082,361. The company has a market capitalization of $8.01 million, a price-to-earnings ratio of -0.51 and a beta of 1.78. The company has a current ratio of 1.19, a quick ratio of 1.04 and a debt-to-equity ratio of 0.16. HeartSciences has a one year low of $1.63 and a one year high of $4.30. The company has a 50-day moving average of $2.17 and a 200 day moving average of $2.52.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new stake in HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent filing with the SEC. Institutional investors own 17.24% of the company’s stock.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.